On the occasion of National Epilepsy Day, GNRC Hospitals held a press conference at its Dispur unit to draw attention to the ...

Q3 2025 Earnings Call Transcript November 14, 2025 MiNK Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

But in findings presented at the American College of Allergy, Asthma and Immunology (ACAAI) meeting in Orlando, the novel ...

When patients present with progressive keratoconus in both eyes, it is important to ensure that they don’t become lost to ...

As biologic options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works ...

Autolus Therapeutics plc is continuing its work to become a pioneering cell therapy company in the space of AD. Learn more ...

TriKE® for relapsed or refractory (r/r) CD33expressing hematologic malignancies continues to actively enroll with ...

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...

New data show that dual-target CAR T therapy induces durable remissions in children with high-risk B-cell leukaemia, offering ...

This advisory highlights more than 100 poster abstracts that will be presented at ASH 2025 involving researchers ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

We read with interest the FUTURE study by Mohamed Abdel-Fattah and colleagues, which reported on the role and cost-effectiveness of urodynamic testing in women with refractory overactive bladder ...